Objective

2

To comprehensively evaluate the advantages and characteristics of

Tenghuang Jiangu Tablets

in the treatment of knee osteoarthritis （KOA） and clarify their clinical positioning.

Methods

2

Methods from evidence-based medicine， clinical epidemiology， clinical medicine， evidence-based pharmacy， pharmacoeconomics， mathematical statistics， and health technology assessment were applied. Based on a multi-criteria decision-making analysis model and clinical evidence and value evaluation software for Chinese patent medicines， the "6+1" dimensional evidence of

Tenghuang Jiangu Tablets

in treating KOA was comprehensively collated and its clinical value evaluated.

Results

2

The adverse reactions of

Tenghuang Jiangu Tablets

mainly involve the gastrointestinal system. Safety evidence is relatively sufficient， and conclusions are clear. Tenghuang Jiangu tablets are effective in reducing the Western Ontario and McMaster Universities Osteoarthritis Index （WOMAC） total score， restoring function， improving stiffness， relieving pain， and enhanci

ng clinical efficacy in KOA， with sufficient efficacy evidence and confirmed results. Based on WOMAC scores， using

Tenghuang Jiangu Tablets

in KOA patients is more cost-effective than conventional treatment alone， with sufficient economic evidence and confirmed results. Evidence on the innovation， suitability， and accessibility of

Tenghuang Jiangu Tablets

is sufficient， with clear results.

Tenghuang Jiangu Tablets

are widely used in the treatment of KOA. Based on the TCM theory of "treating bone by first treating the kidney"， they have distinctive TCM characteristics， with sufficient evidence and clear conclusions.

Conclusion

2

Tenghuang Jiangu Tablets

have high clinical value. It is recommended to conduct safety mechanism studies for serious adverse reactions， carry out high-level， high-quality efficacy studies along with economic evaluations， and explore precision medication mechanisms guided by clinical value.